妊娠期类风湿关节炎低疾病活动度与缓解的临床相关因素
本研究基于Pregnancy-Induced Amelioration of Rheumatoid Arthritis前瞻性队列中190次妊娠的数据,从孕早期随访至分娩,采用多因素回归分析孕晚期疾病活动度(DAS28-CRP-3)的相关因素。结果显示,孕早期DAS28-CRP-3、孕早期泼尼松使用及自身抗体阳性与孕晚期低疾病活动度(DAS28-CRP-3<3.2)负相关(P<0.05),其中孕早期DAS28-CRP-3与自身抗体亦与缓解(DAS28-CRP-3<2.6)相关(P<0.001);亚组分析提示泼尼松与自身抗体的关联仅见于孕早期中高疾病活动度(DAS28-CRP-3≥3.2)者。
要点
- 孕早期DAS28-CRP-3低者,无论自身抗体状态或是否用泼尼松,孕晚期多能达到低疾病活动度或缓解。
- 孕早期泼尼松使用与自身抗体阳性仅在中高疾病活动度患者中与孕晚期低疾病活动度负相关。
- 孕早期疾病活动度较高的患者若未用泼尼松且自身抗体阴性,孕晚期仍有相当机会达到低疾病活动度。
核心结论
- 孕早期DAS28-CRP-3低的RA患者(不论自身抗体状态或泼尼松使用)在孕晚期较可能达到低疾病活动度或缓解。
- 孕早期疾病活动度较高、未使用泼尼松且自身抗体阴性的女性,在孕晚期仍有相当机会达到低疾病活动度。
研究设计与样本
- 研究嵌套于Pregnancy-Induced Amelioration of Rheumatoid Arthritis前瞻性队列研究,纳入190次妊娠,数据覆盖孕早期至分娩。
- 对孕晚期疾病活动度(DAS28-CRP-3)进行多因素回归分析,自变量包括孕早期DAS28-CRP-3、孕早期泼尼松与柳氮磺吡啶使用、产次、既往甲氨蝶呤使用、自身抗体状态、骨侵蚀及RA病程。
主要发现
- 多因素回归中,孕早期DAS28-CRP-3、孕早期泼尼松使用及自身抗体阳性与孕晚期低疾病活动度(DAS28-CRP-3<3.2)负相关(P<0.05)。
- 孕早期DAS28-CRP-3与自身抗体阳性亦与孕晚期缓解(DAS28-CRP-3<2.6)相关(P<0.001)。
- 亚组分析显示,泼尼松使用与自身抗体的上述关联仅存在于孕早期中高疾病活动度(DAS28-CRP-3≥3.2)的患者中。
关键数值与推荐
- 低疾病活动度定义为孕晚期DAS28-CRP-3<3.2,缓解定义为孕晚期DAS28-CRP-3<2.6。
- 孕早期中高疾病活动度定义为DAS28-CRP-3≥3.2。
临床怎么用
- 孕早期可依据DAS28-CRP-3评估孕晚期疾病活动度走向,DAS28-CRP-3低者预后较好。
- 对孕早期中高疾病活动度患者,需关注泼尼松使用与自身抗体阳性对孕晚期疾病活动度的不利关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify a combination of clinical factors associated with low disease activity and remission in the third trimester during pregnancy in women with rheumatoid arthritis (RA). METHODS: This study is embedded in the Pregnancy-Induced Amelioration of Rheumatoid Arthritis study, a prospective cohort study. There were data available on 190 pregnancies from first trimester until delivery. Multivariate regression analyses were performed on the disease activity (Disease Activity Score in 28 joints [DAS28] using the C-reactive protein [CRP] level) in the third trimester. Independent covariates were the DAS28-CRP-3 in first trimester, prednisone and sulfasalazine use in the first trimester, parity, methotrexate use in the past, autoantibody status, the presence of erosions, and RA disease duration. RESULTS: In multivariate regression models, the DAS28-CRP-3, use of prednisone in the first trimester, and the presence of autoantibodies were negatively associated with low disease activity (DAS28-CRP-3 <3.2) in the third trimester (P < 0.05), and the DAS28-CRP-3 and presence of autoantibodies were also associated with remission (DAS28-CRP-3 <2.6) (P < 0.001). Subgroup analysis revealed that the associations of prednisone use and presence of autoantibodies were only present in patients with moderate-to-high disease activity (DAS28-CRP-3 ≥3.2) in the first trimester. CONCLUSION: RA patients who have a low DAS28-CRP-3 in the first trimester (irrespective of autoantibody status or prednisone use) are likely to have low disease activity or remission in the third trimester. Also, women with higher disease activity who are not taking prednisone and who express no autoantibodies still have a fair chance of low disease activity in the last trimester.
引用
- Ince-Askan H, Hazes JMW, Dolhain RJEM, et al. Identifying Clinical Factors Associated With Low Disease Activity and Remission of Rheumatoid Arthritis During Pregnancy. Arthritis Care Res (Hoboken). 2017. PMID: 27813290. doi:10.1002/acr.23143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。